Additionally, in this type of AML, the prevalence of ten-eleven translocation 2 (TET2) is up to 50% in M4 cases, which significantly differs from MDS and other AML types characterized by the presence of 10% to 20% TET2 mutation. The gene discussed is TET2; the disease is myelodysplastic syndrome.